Showing results (11-20 of 47) with videos related to

Sort By:
Pageof 5
Annales De Chirurgie Plastique Et Esthetique|July 3, 2007
Malignant melanoma of soft parts. A "non plastic surgeon's land"?J C Rivera, T Lesimple, E Garin, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 24, 2001
Treatment of metastatic renal cell carcinoma with activated autologous macrophages and granulocyte--macrophage colony-stimulating factorT Lesimple, A Moisan, F Guillé, et al.
European Journal of Nuclear Medicine|March 1, 1995
Per operative localization of a carcinoid tumour of the breast using indium-111 pentetreotide and a nuclear surgical probeB Meunier, J Le Cloirec, L Dazord, et al.
Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction|January 1, 1995
[Malignant melanoma of the vagina. Two case reports. Review of the literature]J Levêque, B Meunier, P Poulain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2000
Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le CancerS Négrier, A Caty, T Lesimple, et al.
Annales De Dermatologie Et De Venereologie|April 20, 2025
The impact of the time-of-day in the administration of immunotherapy and its efficacy in patients with advanced melanoma: A retrospective observational studyM Amici, E Neveu, F Poizeau, et al.
Oncology|November 29, 2002
A phase II study with 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX-4 regimen) in patients with metastatic renal cell carcinomaJ Bennouna, R Delva, F Gomez, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|May 31, 2008
[Merkel cell carcinoma: outcome and role of radiotherapy]R Salvador Alonso, I Lahbabi, M Ben Hassel, et al.
Bulletin Du Cancer|May 14, 2009
Impact of clinical practice guidelines on the management for carcinomas of unknown primary site: a controlled "before-after" studyP Sève, J Mackey, M Sawyer, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2002
Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiformeE Raymond, M Campone, R Stupp, et al.
Pageof 5